Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Cantor Fitzgerald
Daiichi Sankyo
Accenture
Mallinckrodt
Julphar

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 8,425,906

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,425,906
Title:Method to inhibit cancer targeting CD24
Abstract: The present invention relates to a method to inhibit cancer by targeting CD24, more precisely a method to inhibit cancer by using CD24 expressed in most cancer cells as a target of an antibody therapeutic agent or by inhibiting the interaction between CD24 and P-selectin. CD24 is over-expressed in most cancer cells and CD24 accumulated in cytoplasm accelerates metastasis. Therefore, the method to inhibit cancer of the invention by targeting CD24 can be effectively used for the treatment of cancer by inhibiting the progress of various cancers over-expressing CD24.
Inventor(s): Shin; Young Kee (Seoul, KR), Choi; Yoon-La (Seoul, KR), Park; Young Woo (Daejeon-si, KR), Lee; Seung Hyun (Anyang-si, KR), Song; Kyoung (Incheon, KR)
Assignee: SNU R&DB Foundation (Seoul, KR)
Application Number:12/307,108
Patent Claims:see list of patent claims

Details for Patent 8,425,906

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26 ➤ Sign Up SNU R&DB Foundation (Seoul, KR) 2026-06-30 RX search
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24 ➤ Sign Up SNU R&DB Foundation (Seoul, KR) 2026-06-30 RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ➤ Sign Up SNU R&DB Foundation (Seoul, KR) 2026-06-30 RX Orphan search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02 ➤ Sign Up SNU R&DB Foundation (Seoul, KR) 2026-06-30 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Fish and Richardson
Fuji
US Department of Justice
Argus Health
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.